California voters will decide Proposition 38 on November 3, 2026, which would authorize an $8.4 billion general obligation bond for immunology and immunotherapy research, split between a University of California-affiliated institute and grants to public or nonprofit institutions, with half directed to cancer, heart disease, and Alzheimer’s studies. Trader consensus favoring rejection at 56.5% reflects fiscal concerns over the estimated $500–600 million annual General Fund repayment cost for roughly 20–25 years, equivalent to about 0.25% of the state budget, amid competing bond measures and broader budget pressures. The measure includes provisions for 10% royalty returns to offset costs, 2% administrative caps, and discounted treatments for Californians, yet skepticism persists about net fiscal impact and prioritization relative to other November ballot items. No major new developments have emerged since the initiative qualified in June 2026.